肿瘤基础与临床
腫瘤基礎與臨床
종류기출여림상
JOURNAL OF BASIC AND CLINICAL ONCOLOGY
2015年
4期
305-307
,共3页
陈森%梁百晖%吴冬梅
陳森%樑百暉%吳鼕梅
진삼%량백휘%오동매
宫颈癌%放疗%化疗%奈达铂%紫杉醇
宮頸癌%放療%化療%奈達鉑%紫杉醇
궁경암%방료%화료%내체박%자삼순
cervical cancer%radiotherapy%chemotherapy%nedaplatin%paclitaxel
目的:分析同步放疗联合奈达铂、紫杉醇治疗局部晚期宫颈癌的临床疗效和毒副反应。方法60例局部晚期宫颈癌患者按入院先后顺序分2组,每组30例,对照组患者给予单纯放疗,观察组在对照组的基础上同时给予奈达铂、紫杉醇化疗。结果观察组总有效率为90.00%,高于对照组的56.67%,差异有统计学意义(P <0.05)。2组1 a 无复发生存率和1 a 无远处转移生存率比较差异均无统计学意义( P >0.05)。2组主要毒副反应均为胃肠道反应和骨髓抑制,总发生率比较差异均无统计学意义( P >0.05)。结论同步放疗联合奈达铂、紫杉醇治疗局部晚期宫颈癌近期疗效显著,毒副反应可耐受。
目的:分析同步放療聯閤奈達鉑、紫杉醇治療跼部晚期宮頸癌的臨床療效和毒副反應。方法60例跼部晚期宮頸癌患者按入院先後順序分2組,每組30例,對照組患者給予單純放療,觀察組在對照組的基礎上同時給予奈達鉑、紫杉醇化療。結果觀察組總有效率為90.00%,高于對照組的56.67%,差異有統計學意義(P <0.05)。2組1 a 無複髮生存率和1 a 無遠處轉移生存率比較差異均無統計學意義( P >0.05)。2組主要毒副反應均為胃腸道反應和骨髓抑製,總髮生率比較差異均無統計學意義( P >0.05)。結論同步放療聯閤奈達鉑、紫杉醇治療跼部晚期宮頸癌近期療效顯著,毒副反應可耐受。
목적:분석동보방료연합내체박、자삼순치료국부만기궁경암적림상료효화독부반응。방법60례국부만기궁경암환자안입원선후순서분2조,매조30례,대조조환자급여단순방료,관찰조재대조조적기출상동시급여내체박、자삼순화료。결과관찰조총유효솔위90.00%,고우대조조적56.67%,차이유통계학의의(P <0.05)。2조1 a 무복발생존솔화1 a 무원처전이생존솔비교차이균무통계학의의( P >0.05)。2조주요독부반응균위위장도반응화골수억제,총발생솔비교차이균무통계학의의( P >0.05)。결론동보방료연합내체박、자삼순치료국부만기궁경암근기료효현저,독부반응가내수。
Objective To investigate the clinical efficacy and toxicities of concurrent radiotherapy combined with nedaplatin and paclitaxel for locally advanced cervical cancer. Methods Sixty patients with locally advanced cervi-cal cancer were divided into the control group and the observation group. The 30 patients in the control group were treated with radiotherapy,while the 30 patients in the observation group were treated with concurrent radiotherapy plus nedaplatin and paclitaxel. Results The total response rate was 90. 00% in the observation group,and was 56. 67% in the control group(P < 0. 05). There was no statistical difference in the 1- year recurrence-free survival rate and the 1-year distant metastasis-free survival rate between the two groups(P > 0. 05). There was no statistical difference in the gastrointestinal reaction and marrow depression between the two groups(P > 0. 05). Conclusion Concurrent radiotherapy combined with nedaplatin and paclitaxel is effective and safe for locally advanced cervical cancer.